Current and future use of umifenovir in patients with COVID-19

At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical. The published clinical trials have contradicting results. The decision to use umifenovir in COVID-19 should be individualized, considering the “experimental” nature of this treatment.

Bibliographic Details
Published in:	Качественная клиническая практика
Main Authors:	Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, K. B. Mirzaev, V. A. Otdelenov, V. M. Tsvetov, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev
Format:	Article
Language:	Russian
Published:	Izdatelstvo OKI 2020-10-01
Subjects:	коронавирус умифеновир covid-19
Online Access:	https://www.clinvest.ru/jour/article/view/532

Similar Items

Current and future use of remdesivir in patients with COVID-19
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Rationale for use mefloquine for COVID-19 treatment
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Current and future use of dipyridamole in patients with COVID-19
by: I. S. Burashnikova, et al.
Published: (2020-10-01)

Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Current and future use of favipiravir in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

Current and future use of colchicine in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge
by: A. V. Krykov, et al.
Published: (2020-10-01)

Dexamethasone use in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Could canakinumab be used for COVID-19?
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Current and future use of angiotensin II receptor blockers in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

Possibilities for the use of anakinra in COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Rationality of routine clinical use of olokizumab in COVID-19
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Is it possible to use riamilovir to prevent infection and treat COVID-19?
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Current and future use of vitamin D<sub>3</sub> in patients with COVID-19
by: I. N. Sychev, et al.
Published: (2020-10-01)

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Possibility for the use of bromhexine to prevent infection with SARS-CoV-2
by: K. A. Zagorodnikova, et al.
Published: (2020-10-01)

Possibilities for the use of tofacitinib in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab
by: K. B. Mirzaev, et al.
Published: (2020-10-01)

Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention
by: K. B. Mirzaev, et al.
Published: (2020-10-01)

Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Influenza in today: direct-acting antiviral therapy
by: T. V. Sologub
Published: (2015-12-01)

Damage of the Muscle System in Covid-19
by: I. T. Murkamilov, et al.
Published: (2021-03-01)

OXYGEN THERAPY MANAGEMENT IN THE TREATMENT OF PATIENTS WITH NEW CORONAVIRUS INFECTION
by: Михаил Исаакович Ликстанов, et al.
Published: (2021-11-01)

Media Representation of the Pandemic: a Metaphorical Image of War (based on American Newspapers)
by: N. S. Dankova, et al.
Published: (2020-08-01)

PREPARATION AND FUNCTIONING OF ENGINEERING SYSTEMS IN THE CONDITIONS OF A REPROFILED COVIDATE HOSPITAL
by: Михаил Исаакович Ликстанов, et al.
Published: (2020-09-01)

EXPERIENCE IN ORGANIZING CARE FOR PATIENTS WITH CORONAVIRUS INFECTION IN A REDESIGNED INFECTIOUS DISEASES HOSPITAL
by: Михаил Исаакович Ликстанов, et al.
Published: (2021-04-01)

EXPERIENCE IN THE ORGANIZATION OF MEDICAL CARE FOR PATIENTS IN A MULTIDISCIPLINARY HOSPITAL IN THE CONDITIONS OF THE COVID-19 PANDEMIC
by: Игорь Вадимович Пачгин, et al.
Published: (2021-06-01)

ORGANIZATION OF "OPEN REANIMATION" IN THE REPROFILED INFECTIOUS HOSPITAL
by: Виталий Сергеевич Самоделкин, et al.
Published: (2021-06-01)

ORGANIZATION OF MEALS FOR PATIENTS WITH CORONAVIRUS INFECTION IN A RE-PROFILED INFECTIOUS DISEASES HOSPITAL
by: Михаил Исаакович Ликстанов, et al.
Published: (2020-11-01)

Antioxidant Potential of Antiviral Drug Umifenovir
by: Elena V. Proskurnina, et al.
Published: (2020-03-01)

Comparative Effectiveness of Riamilovir and Umifenovir for Treating Influenza
by: A. F. Popov, et al.
Published: (2021-06-01)

CLINICAL AND PATHOLOGOANATOMIC CHARACTERISTICS OF ADVERSE OUTCOMES OF SARS-COV-2 IN A LEVEL III HOSPITAL
by: Михаил Исаакович Ликстанов, et al.
Published: (2022-03-01)

DOMESTIC SPECTRUM OF ANTIVIRAL DRUG — UMIFENOVIR AS ETIOTROPIC THERAPY OF INFLUENZA
by: L. V. Osidak, et al.
Published: (2016-09-01)

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population
by: K. B. Mirzaev, et al.
Published: (2019-07-01)